FIGURE 8.

(A) Representative fluorescence angiography images (Heidelberg Engineering, Heidelberg Eye Explorer) of 6 laser-induced lesions per eye in rats treated with vehicle control (veh) or RG7774 1, 3, or 10 mg/kg via oral gavage, 1 day before and 7 days after laser injury. (B) Mean ± standard deviation (SD) lesion (hyperfluorescence) areas per eye determined by fluorescent angiography after intravenous (IV) injection of fluorescein in rats with laser-induced choroidal neovascularization (CNV) treated with vehicle control (n = 23 eyes) or RG7774 0.01 (n = 5 eyes), 0.03 (n = 5 eyes), 0.1 (n = 10 eyes), 0.3 (n = 5 eyes), 1.0 (n = 10 eyes), 3.0 (n = 13 eyes), 10 mg/kg (n = 13 eyes) via oral gavage. (C) Quantitative analysis of microglia migration toward laser-injured retinal regions in rats treated with vehicle control or RG7774 (3 and 10 mg/kg) via oral gavage. Data in (C) are shown as mean ± standard error of the mean (SEM) with 4, 5 and 5 stacks in non-lasered regions (patterned bars) and 24, 29 and 30 stacks in lasered regions for the vehicle, 3 and 10 mg/kg groups, respectively (solid bars). *p < 0.05; ***p < 0.001 based on 1-way analysis of covariance (ANOVA), followed by Newman–Keuls post hoc analysis. ED₅₀: effective dose in 50% of animals.